H22肝癌荷瘤小鼠最佳中药个体化治疗方案的探索和研究  

Experimental Study of Optimal Individualized TCM Therapeutic Regimen on H22 Hepatocarcinoma Mice

作　　者：张园园[1] 方肇勤[1] 王艳明[1] 潘志强[1] 卢文丽[1] 刘小美[1] 

机构地区：[1]上海中医药大学,上海201203

出　　处：《中华中医药学刊》2014年第4期745-748,I0004,I0005,共6页Chinese Archives of Traditional Chinese Medicine

基　　金：国家科技重大专项课题(2009ZX09502-018);上海市教委学科建设项目

摘　　要：目的:探索H22肝癌小鼠的中药个体化最佳治疗方案。方法:昆明种雄性小鼠腋下接种H22腹水瘤细胞,将中药个体化辨证论治联合肿瘤局部介入化疗/索拉非尼口服综合治疗方案进行调整:对预判预后可能较差者,给予积极治疗,预后可能较好者缓治,并运用小鼠标准化、计量化辨证方法,观察调整后的方案及肿瘤局部介入化疗/索拉非尼口服单纯西医治疗方案对小鼠带瘤生存时间、抑瘤率和证候的影响。结果:前者延长小鼠带瘤生存时间的作用较好(与对照组比较,P<0.05),然而对气血阴阳证候以及胸腺和脾脏指数等指标的影响,未表现出明显的优势。结论:调整后的中药个体化辨证论治方案为H22肝癌荷瘤小鼠的有效治疗方案,其还有待于进一步的优化以成为最佳治疗方案。Objective：To explore the best individualized traditional Chinese medicine therapeutic regimen on H22 hep- atoearcinoma mice. Methods ： Kunming male mice were injected with H22 tumor cells and the standardized and quantitative of syndrome differentiation methods or Sorafenib oral comprehensive treatment program was regulated. Those who have poor prognosis were given active treatment while those with good prognosis given treatment slowly. By standardized and quantitative of syndrome differentiation methods, the regulated program was observed and the influence on survival rate,in- hibiting rate and syndrome differentiation. Results ： The former was better in WTS （ compared with control group, P 〈 0.05 ） , but it had no certain superiority in survival time, the syndrome of qi, blood, Yin and Yang, and thymus and spleen weight. Conclusion： The adjusted therapeutic regimen was better on H22 hepatocarcinoma mice, and it needed further op- timized treatment.

关 键 词：肝癌 小鼠 中药 个体化治疗 

分 类 号：R735.7[医药卫生—肿瘤]